As of March 2026, the Ozempic litigation (MDL 3094) has reached a critical phase with over 3,300 active cases pending in federal court. If you suffered from gastroparesis, ileus, or severe vision loss (NAION) after using semaglutide, understanding the latest payout eligibility requirements is essential to securing compensation.
The lawsuits against Novo Nordisk allege that the manufacturer failed to adequately warn patients about the risk of “stomach paralysis” a condition where the digestive system slows down significantly, leading to chronic vomiting and hospitalization.
2026 Payout Eligibility: The “Gastric Emptying” Rule
In recent court orders from the Eastern District of Pennsylvania, Judge Gene E.K. Marston has clarified a major requirement for claimants. To be eligible for a payout in 2026, most plaintiffs must provide:
- A Confirmed Diagnosis: Medical records showing gastroparesis or intestinal blockage.
- The Scintigraphy Test: Proof of a “Gastric Emptying Study” performed at the time of injury to confirm the delayed motility.
- Hospitalization Records: Evidence of ER visits or inpatient care due to daily vomiting or malnutrition lasting at least four weeks.
Estimated Settlement Amounts for 2026
While no global settlement has been signed yet, legal experts are projecting payout tiers based on the severity of the gastrointestinal damage:
- Tier 1 ($400,000 – $700,000+): Severe cases involving permanent impairment, surgery, or multiple hospitalizations.
- Tier 2 ($150,000 – $400,000): Cases with documented chronic gastroparesis requiring long-term medical management.
- Tier 3 ($50,000 – $150,000): Claims involving significant pain and suffering but with shorter recovery periods.
New Vision Loss Claims (NAION)
A second wave of litigation has emerged in early 2026 regarding NAION (Non-Arteritic Anterior Ischemic Optic Neuropathy), a condition that can cause sudden blindness. If you experienced vision loss while on Ozempic or Wegovy, your case may now be consolidated into a specialized track within the MDL.
How to Access MDL 3094 Court Records
The official proceedings are being held in the U.S. District Court for the Eastern District of Pennsylvania. Claimants are advised to monitor the “Bellwether” trial dates set for late 2026, as these initial verdicts will set the pace for all future settlement offers.
Sources & Legal References:
- U.S. District Court – Eastern District of Pennsylvania (MDL 3063/3094 Official Docket)
- FDA – Warning Letter to Novo Nordisk Regarding Adverse Event Reporting (March 2026)
- MDL Statistics – U.S. Judicial Panel on Multidistrict Litigation